Genfit S.A. (OTCMKTS:GNFTF) Short Interest Up 1,622.2% in March

Genfit S.A. (OTCMKTS:GNFTF) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 15,500 shares, an increase of 1,622.2% from the March 15th total of 900 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Genfit Price Performance

Shares of GNFTF stock opened at $3.54 on Wednesday. Genfit has a one year low of $2.95 and a one year high of $5.55. The company’s 50-day simple moving average is $3.54 and its 200-day simple moving average is $4.36.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.